ImmunoGen
is a Massachusetts-based biotechnology company that researches and develops antibody-drug conjugate therapeutics for the treatment of cancer... Read moreImmunoGen
is a Massachusetts-based biotechnology company that researches and develops antibody-drug conjugate therapeutics for the treatment of cancer... Read more
1980
PrivateAcquired by AbbVie, Inc.
News
May 28, 2026
Newsbreak
ImmunoGen: With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
May 15, 2025
Benzinga
ImmunoGen: Daniel M Junius At IDEXX Laboratories Capitalizes: Options Exercised, Resulting In $658K
Jan 25, 2025
Via
ImmunoGen: ImmunoGen And Xenetic Biosciences On The List Of Winners And Losers Of Monday's US Premarket Session
Jun 06, 2024
Marketwirenews
ImmunoGen: ABBV - AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients | Benzinga
Mar 22, 2024
Seeking Alpha
ImmunoGen: FDA grants full approval to AbbVie/ImmunoGen drug Elahere
Mar 22, 2024
MarketScreener
ImmunoGen: AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal
Feb 22, 2024
Deal
ImmunoGen: New Form 15-12G for ImmunoGen, Inc.
Feb 21, 2024
Nasdaq
ImmunoGen: AbbVie eyes selling at least $13 bln of bonds to fund M&A, Bloomberg reports
Feb 12, 2024
MarketWatch
ImmunoGen: AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen
Feb 08, 2024
Financialcontent
ImmunoGen: ImmunoGen Inc. (NASDAQ: IMGN) Near Top of Volume Charts in Thursday Trading
ImmunoGen Competitors
1
2
3
4
5
6
7
8
9
10